Biorestorative Therapies, Inc. (NASDAQ:BRTX) Short Interest Down 80.6% in June

Biorestorative Therapies, Inc. (NASDAQ:BRTX) saw a large decline in short interest during the month of June. As of June 15th, there was short interest totaling 1,281,247 shares, a decline of 80.6% from the May 31st total of 6,588,718 shares. Based on an average trading volume of 1,895,030 shares, the short-interest ratio is currently 0.7 days. Approximately 5.8% of the company’s stock are sold short.

Institutional Trading of Biorestorative Therapies

Several institutional investors and hedge funds have recently modified their holdings of BRTX. DRW Securities LLC purchased a new position in shares of Biorestorative Therapies during the 4th quarter valued at $55,000. Citadel Advisors LLC bought a new stake in Biorestorative Therapies during the third quarter valued at about $152,000. Finally, Virtu Financial LLC lifted its position in shares of Biorestorative Therapies by 102.4% in the third quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock valued at $35,000 after acquiring an additional 12,319 shares in the last quarter. 69.38% of the stock is currently owned by institutional investors.

Biorestorative Therapies Price Performance

Shares of BRTX traded down $0.01 on Friday, reaching $0.38. The company’s stock had a trading volume of 291,671 shares, compared to its average volume of 2,201,984. Biorestorative Therapies has a 12-month low of $0.16 and a 12-month high of $1.89. The stock’s 50 day simple moving average is $0.30 and its two-hundred day simple moving average is $0.56. The stock has a market capitalization of $9.68 million, a P/E ratio of -0.36 and a beta of 0.67.

Biorestorative Therapies (NASDAQ:BRTX) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.01. Biorestorative Therapies had a negative return on equity of 508.42% and a negative net margin of 3,088.27%.The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.31 million. Analysts expect that Biorestorative Therapies will post -0.66 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Biorestorative Therapies in a research note on Wednesday, May 27th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

About Biorestorative Therapies

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.